Andreea L Seritan1, James A Bourgeois2, Andrea Schneider3, Yi Mu4, Randi J Hagerman3, Danh V Nguyen4. 1. Department of Psychiatry and Behavioral Sciences, University of California Davis Medical Center, Sacramento, California ; Medical Investigation of Neurodevelopmental Disorders (M.I.N.D.) Institute, University of California Davis Medical Center, Sacramento, California. 2. Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada. 3. Medical Investigation of Neurodevelopmental Disorders (M.I.N.D.) Institute, University of California Davis Medical Center, Sacramento, California ; Department of Pediatrics, University of California Davis Medical Center, Sacramento, California. 4. Department of Public Health Sciences, University of California Davis, Davis, California.
Abstract
OBJECTIVE: FMR1 premutation carriers of both genders have a high lifetime prevalence of anxiety and depressive disorders, however little is known regarding the onset ages of these conditions. This study compared onset ages of mood and anxiety disorders in premutation carriers with typical onset ages of the same disorders in the general population. METHODS: Eighty-one premutation carriers (42% men; average age 62, SD 10) with and without FXTAS completed the Structured Clinical Interview for DSM-IV-TR. Onset ages of mood and anxiety disorders were compared to the corresponding typical population onset ages using the signed rank test. RESULTS: Overall median onset ages of MDD (46 years old, p < 0.0001), panic disorder (40 years old, p = 0.0067), and specific phobia (11.5 years old, p = 0.0003) were significantly higher in premutation carriers compared to the general population. Median MDD onset ages in male carriers (52 years old) and those with FXTAS (49.5 years old) were significantly higher relative to the general population (median 32, both p < 0.0001). Tremor and ataxia emerged significantly later than MDD and the anxiety disorders studied. CONCLUSION: Depressive and anxiety disorders in premutation carriers have a later onset compared to the general population, but precede the onset of motor symptoms. This may be due to progressive mRNA toxicity in the limbic system, white matter changes leading to neuronal dysconnectivity, and interaction with environmental factors. Psychosocial factors may be protective. Further research is needed to understand the full spectrum of psychiatric phenotypes in FMR1 premutation carriers.
OBJECTIVE:FMR1 premutation carriers of both genders have a high lifetime prevalence of anxiety and depressive disorders, however little is known regarding the onset ages of these conditions. This study compared onset ages of mood and anxiety disorders in premutation carriers with typical onset ages of the same disorders in the general population. METHODS: Eighty-one premutation carriers (42% men; average age 62, SD 10) with and without FXTAS completed the Structured Clinical Interview for DSM-IV-TR. Onset ages of mood and anxiety disorders were compared to the corresponding typical population onset ages using the signed rank test. RESULTS: Overall median onset ages of MDD (46 years old, p < 0.0001), panic disorder (40 years old, p = 0.0067), and specific phobia (11.5 years old, p = 0.0003) were significantly higher in premutation carriers compared to the general population. Median MDD onset ages in male carriers (52 years old) and those with FXTAS (49.5 years old) were significantly higher relative to the general population (median 32, both p < 0.0001). Tremor and ataxia emerged significantly later than MDD and the anxiety disorders studied. CONCLUSION:Depressive and anxiety disorders in premutation carriers have a later onset compared to the general population, but precede the onset of motor symptoms. This may be due to progressive mRNA toxicity in the limbic system, white matter changes leading to neuronal dysconnectivity, and interaction with environmental factors. Psychosocial factors may be protective. Further research is needed to understand the full spectrum of psychiatric phenotypes in FMR1 premutation carriers.
Entities:
Keywords:
FMR1 premutation; MDD; anxiety; depression; fragile X tremor/ataxia syndrome (FXTAS); onset age
Authors: David Hessl; Flora Tassone; Danuta Z Loesch; Elizabeth Berry-Kravis; Maureen A Leehey; Louise W Gane; Ingrid Barbato; Cathlin Rice; Emma Gould; Deborah A Hall; James Grigsby; Jacob A Wegelin; Susan Harris; Foster Lewin; Dahlia Weinberg; Paul J Hagerman; Randi J Hagerman Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2005-11-05 Impact factor: 3.568
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters Journal: Arch Gen Psychiatry Date: 2005-06
Authors: Sarah M Coffey; Kylee Cook; Nicole Tartaglia; Flora Tassone; Danh V Nguyen; Ruiqin Pan; Hannah E Bronsky; Jennifer Yuhas; Mariya Borodyanskaya; Jim Grigsby; Melanie Doerflinger; Paul J Hagerman; Randi J Hagerman Journal: Am J Med Genet A Date: 2008-04-15 Impact factor: 2.802
Authors: Theresa E Perlis; Don C Des Jarlais; Samuel R Friedman; Kamyar Arasteh; Charles F Turner Journal: Addiction Date: 2004-07 Impact factor: 6.526
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: Jim Grigsby; Angela G Brega; Rachael E Bennett; James A Bourgeois; Andreea L Seritan; Glenn K Goodrich; Randi J Hagerman Journal: Clin Neuropsychol Date: 2016-06-29 Impact factor: 3.535
Authors: J-C Yang; C Simon; A Schneider; A L Seritan; L Hamilton; P J Hagerman; R J Hagerman; J M Olichney Journal: Genes Brain Behav Date: 2013-12-26 Impact factor: 3.449
Authors: Aaron D Besterman; Scott A Wilke; Tua-Elisabeth Mulligan; Stephen C Allison; Randi Hagerman; Andreea L Seritan; James A Bourgeois Journal: Future Neurol Date: 2014-03
Authors: Anne C Wheeler; Donald B Bailey; Elizabeth Berry-Kravis; Jan Greenberg; Molly Losh; Marsha Mailick; Montserrat Milà; John M Olichney; Laia Rodriguez-Revenga; Stephanie Sherman; Leann Smith; Scott Summers; Jin-Chen Yang; Randi Hagerman Journal: J Neurodev Disord Date: 2014-07-30 Impact factor: 4.025